Patents Assigned to New York Blood Center, Inc.
  • Patent number: 8968993
    Abstract: The disclosure provides methods of making a cell-containing product having a uniform amount of cells therein. The method comprises pooling red blood cells from a plurality of blood units, and inactivating any pathogen contained therein. A storage solution added to the cellular component results in a cell-containing product that is essentially pathogen and white blood cell free and has an extended shelf life of about 42 to about 100 days. The cell-containing product is further divided into units which comprise a uniform dose of RBCs per unit.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: March 3, 2015
    Assignee: The New York Blood Center, Inc.
    Inventors: Beth H. Shaz, Christopher D. Hillyer
  • Patent number: 8940864
    Abstract: Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus in a cell. Also provided are methods of treating a mammal infected with a capsid-containing virus. Further provided are methods of treating a mammal at risk for infection with a capsid-containing virus. Methods of making the above peptides are additionally provided, as are uses of the above peptides and pharmaceutical compositions.
    Type: Grant
    Filed: October 2, 2007
    Date of Patent: January 27, 2015
    Assignee: New York Blood Center, Inc.
    Inventors: Asim Kumar Debnath, Hongtao Zhang, Qian Zhao
  • Patent number: 8937154
    Abstract: Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: January 20, 2015
    Assignee: New York Blood Center, Inc.
    Inventors: Asim Kumar Debnath, Hongtao Zhang, Qian Zhao
  • Patent number: 8933019
    Abstract: Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: January 13, 2015
    Assignee: New York Blood Center, Inc.
    Inventors: Asim Kumar Debnath, Hongtao Zhang, Francesca Curreli
  • Patent number: 8920659
    Abstract: Disclosed herein are centrifuge-free self-contained systems for aseptically separating components of whole blood comprising at least one cassette for receiving whole blood; at least one red blood cell exclusion filter; at least one leukocyte reduction filters; at least one platelet exclusion filter; a plurality of product cassettes; and optionally a plurality of pumps and valves; and wherein the filters, pumps, valves, and cassettes are fluidly connected by tubing and the system does not include a centrifuge. Also disclosed are methods for obtaining blood components using the system.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: December 30, 2014
    Assignee: New York Blood Center, Inc.
    Inventors: Christoper D. Hillyer, Beth H. Shaz
  • Publication number: 20140377219
    Abstract: Chemical compounds that inhibit retroviruses are presented herein. More particularly, this disclosure provides small molecule compounds that inhibit infection with, or treat infection caused by, human immunodeficiency viruses.
    Type: Application
    Filed: September 6, 2012
    Publication date: December 25, 2014
    Applicant: New York Blood CEnter, Inc.
    Inventors: Asim Kumar Debnath, Francesca Curreli, Peter D. Kwong, Young Do Kwon
  • Patent number: 8900585
    Abstract: Disclosed herein are neutralizing antibodies with cross-neutralizing activity and cross-protective effects against divergent stains of influenza virus, which are specific for an epitope having at least 90% homology to amino acids +72-115 of the HA1 domain of H5N1 influenza virus hemagglutinin.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: December 2, 2014
    Assignee: New York Blood Center, Inc.
    Inventors: Shibo Jiang, Lanying Du, Yusen Zhou
  • Patent number: 8828932
    Abstract: Disclosed herein are bifunctional molecules which inactivate human immunodeficiency virus (HIV) even before the virus attacks the target cell and inhibits HIV entry into the target cell. Also disclosed are novel anti-HIV therapeutics for treatment of patients infected by HIV. Further disclosed are methods for prophylaxis against HIV and treatment of HIV infection.
    Type: Grant
    Filed: May 3, 2011
    Date of Patent: September 9, 2014
    Assignee: New York Blood Center, Inc.
    Inventors: Shibo Jiang, Chungen Pan, Lu Lu
  • Patent number: 8828931
    Abstract: Disclosed herein are bifunctional molecules which inhibit HIV entry into the target cell. Also disclosed are novel anti-HIV therapeutics for treatment of patients infected by HIV, including non-B and multi-drug resistant strains.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: September 9, 2014
    Assignee: New York Blood Center, Inc.
    Inventors: Shibo Jiang, Chungen Pan
  • Patent number: 8546439
    Abstract: Chemical compounds that disrupt retroviral assembly and maturation are presented herein. More particularly, this disclosure provides small molecule compounds that disrupt the formation and maturation of virus particles and methods of using such small molecules to treat HIV-1 infection.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: October 1, 2013
    Assignee: New York Blood Center, Inc.
    Inventors: Asim Kumar Debnath, Hongtao Zhang, Francesca Curreli
  • Patent number: 8512942
    Abstract: The disclosure provides methods of making a cell-containing product having a uniform amount of cells therein. The method comprises pooling red blood cells from a plurality of blood units, and inactivating any pathogen contained therein. A storage solution added to the cellular component results in a cell-containing product that is essentially pathogen and white blood cell free and has an extended shelf life of about 42 to about 100 days. The cell-containing product is further divided into units which comprise a uniform dose of RBCs per unit.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: August 20, 2013
    Assignee: New York Blood Center, Inc.
    Inventors: Beth H. Shaz, Christopher D. Hillyer
  • Publication number: 20130209431
    Abstract: Disclosed herein are methods of isolating erythroid progenitor cells from a source of human hematopoietic cells and methods of culturing the isolated erythroid progenitor cells in vitro to produce clinically relevant quantities of erythrocytes.
    Type: Application
    Filed: February 13, 2013
    Publication date: August 15, 2013
    Applicant: NEW YORK BLOOD CENTER, INC.
    Inventor: NEW YORK BLOOD CENTER, INC.
  • Publication number: 20130203090
    Abstract: Disclosed herein are systems and methods for assessing the risk of risk of hemolytic disease of the fetus or neonate, neonatal alloimmune thrombocytopenic purpura, or transfusion-associated lung injury in a patient or transfusion recipient.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 8, 2013
    Applicant: NEW YORK BLOOD CENTER, INC.
    Inventor: NEW YORK BLOOD CENTER, INC.
  • Publication number: 20130143817
    Abstract: Disclosed herein are methods for treating disease, such as diseases of iron overload, including ?-thalassemia, comprising administering at least one course of transferrin and thereby reducing the size of the spleen in said patient and reducing the concentration of iron in the tissues and blood.
    Type: Application
    Filed: December 8, 2010
    Publication date: June 6, 2013
    Applicant: NEW YORK BLOOD CENTER, INC.
    Inventor: Yelena Z. Ginzburg
  • Patent number: 8426210
    Abstract: Disclosed herein are antibodies, systems and methods for assessing the risk of hemolysis following a blood transfusion with crossmatch incompatible blood. The disclosure provides a method for determining the relative hemolytic index and therefore the risk of post-transfusion hemolysis for said patient.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: April 23, 2013
    Assignee: New York Blood Center, Inc.
    Inventor: Gregory R. Halverson
  • Publication number: 20130004458
    Abstract: Chemical compounds that disrupt retroviral assembly and maturation are presented herein. More particularly, this disclosure provides small molecule compounds that disrupt the formation and maturation of virus particles and methods of using such small molecules to treat HIV-1 infection.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 3, 2013
    Applicant: NEW YORK BLOOD CENTER, INC.
    Inventors: Asim Kumar Debnath, Hongtao Zhang, Francesca Curreli
  • Patent number: 8324153
    Abstract: Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
    Type: Grant
    Filed: May 5, 2009
    Date of Patent: December 4, 2012
    Assignee: New York Blood Center, Inc.
    Inventors: Asim Kumar Debnath, Hongtao Zhang, Francesca Curreli
  • Publication number: 20120295285
    Abstract: Disclosed herein are methods for the isolation, identification, and quantification of red blood cells and red blood cell precursors at different developmental stages. Also disclosed are methods for monitoring ex vivo proliferation and differentiation of red blood cells and red blood cell progenitors.
    Type: Application
    Filed: July 13, 2012
    Publication date: November 22, 2012
    Applicant: NEW YORK BLOOD CENTER, INC.
    Inventors: Xiuli An, Mohandas Narla, Jing Liu, Susanne Heck
  • Patent number: 8299093
    Abstract: Chemical compounds that disrupt retroviral assembly and maturation are presented herein. More particularly, this disclosure provides small molecule compounds that disrupt the formation and maturation of virus particles and methods of using such small molecules to treat HIV-1 infection.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: October 30, 2012
    Assignee: New York Blood Center, Inc.
    Inventors: Asim Kumar Debnath, Hongtao Zhang, Francesca Curreli
  • Publication number: 20120258446
    Abstract: The present invention provides a method to diagnostically detect the variants of a given pathogen, such as HIV, hepatitis C, hepatitis B (HBV), Parvovirus B19, etc., with the use of a single detection probe.
    Type: Application
    Filed: April 26, 2012
    Publication date: October 11, 2012
    Applicant: NEW YORK BLOOD CENTER, INC.
    Inventors: Linda Andrus, Carmen Nicola Nichols